Article in ACS chemical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 7 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors at 1 institution in 4 countries.
Broderick C CorlessPharmacology Graduate Program, Weill Cornell Graduate College of Medical Sciences
Raphael GeißenDoctoral Program, Faculty of Biology, Albert-Ludwigs-Universität Freiburg, Schänzlestraße 1, 79104 Freiburg im Breisgau, Germany.
Nicholas A PrescottChemical Biology Program, Sloan Kettering Institute
Yael DavidPharmacology Graduate Program, Weill Cornell Graduate College of Medical SciencesORCID 0000-0003-1696-0025
David A ScheinbergPharmacology Graduate Program, Weill Cornell Graduate College of Medical Sciences
Derek S TanPharmacology Graduate Program, Weill Cornell Graduate College of Medical SciencesORCID 0000-0002-7956-9659
Memorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
T LYMPHOCYTE SUBSET FUNCTION POST-TRANSPLANTATIONP01CA023766 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PERALES, MIGUEL-ANGEL · 1985 to 2023
$59.0M
CANCER PHARMACOLOGYT32CA062948 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LORRAINE J GUDAS · 1994 to 2026
$12.1M
Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.R35CA241894 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DAVID A SCHEINBERG · 2020 to 2026
$7.2M
Investigating histone glycation as a new dynamic epigenetic markR35GM138386 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI DAVID-SHTERNBERG, YAEL E · 2020 to 2024
$2.2M
Tri-Institutional PhD Program in Chemical BiologyT32GM115327 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI TAN, DEREK S · 2015 to 2019
$741k
EpoxySEAKER and onSEAKER: CAR T-Cell Systems for Targeted Local Biosynthesis of Therapeutic WarheadsF31CA261179 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CORLESS, BRODERICK C · 2021 to 2023
$120k
Biochemical studies of aberrant chromatin regulation in cancerF99CA264420 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI PRESCOTT, NICHOLAS · 2021 to 2022
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Chemoenzymatic Synthesis of Novel Cytotoxic Epoxyketones Using the Eponemycin Biosynthetic Enzyme EpnF. · full record | OpenQuestion